Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 Study

Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 - Randomized, Double-Blind, Factorial Study to Compare the Safety and Efficacy of Combinations of GEN-003 and Matrix-M2 in Subjects With Genital HSV-2

This is a voluntary study to allow subjects who received placebo while on GEN-003-002 to be randomized, in a blinded manner, to 1 of 6 active combinations of GEN-003 and Matrix-M2.

Objectives:

• To compare the impact on clinical Herpes Simplex Virus type-2 (HSV-2) disease among 6 different combinations of GEN-003 antigens and Matrix-M2 adjuvant measured by:

  • Time to first clinical and/or virologic recurrence after Dose 3 (Day 43)
  • Proportion of subjects who are recurrence free at 6 and 12 months after the last dose of vaccine
  • Lesion rate (percent of days with genital lesions present) during the post-vaccination follow-up period
  • Antiviral use.
• To evaluate the safety and tolerability of GEN-003 in combination with Matrix-M2.

Study Overview

• Status: Completed
• Conditions: Genital Herpes Simplex Type 2
• Intervention / Treatment: Biological: GEN-003 Vaccine (30μg of each antigen); Biological: Matrix-M2 Adjuvant (25μg); Biological: Matrix-M2 Adjuvant (50μg); Biological: Matrix-M2 Adjuvant (75μg); Biological: GEN-003 Vaccine (60μg of each antigen)

• Study Type: Interventional
• Enrollment (Actual): 37
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Alabama
    • Birmingham, Alabama, United States, 35294-0006
      • University of Alabama Vaccine Research Unit
  • California
    • San Diego, California, United States, 92108
      • Medical Center for Clinical Research
    • San Francisco, California, United States, 94115
      • Quest Clinical Research
  • Illinois
    • Chicago, Illinois, United States, 60612
      • University of Illinois Department of Medicine
  • Indiana
    • Indianapolis, Indiana, United States, 46202
      • Indiana University Infectious Disease Research
  • Massachusetts
    • Boston, Massachusetts, United States, 02215
      • The Fenway Institute
  • North Carolina
    • Chapel Hill, North Carolina, United States, 27599
      • UNC Global HIV Prevention and Treatment Clinical Trials Unit
  • Ohio
    • Cincinnati, Ohio, United States, 45229-3039
      • Cincinnati Children's Hospital Medical Center
  • Oregon
    • Portland, Oregon, United States, 97210
      • Westover Heights Clinic
  • Pennsylvania
    • Pittsburgh, Pennsylvania, United States, 15213
      • Magee-Womens Hospital of UPMC
  • Texas
    • Austin, Texas, United States, 98745
      • Tekton Research
    • Houston, Texas, United States, 77065
      • Center For Clinical Studies
    • Houston, Texas, United States, 77030
      • Center for Clinical Studies - Houston
    • Webster, Texas, United States, 77598
      • Center for Clinical Studies - Clear Lake/Webster
  • Utah
    • Salt Lake City, Utah, United States, 84132
      • University of Utah
  • Washington
    • Seattle, Washington, United States, 98104
      • UW Virology Research Clinic

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years to 48 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Subjects who received placebo in GEN-003-002 and completed the study through Day 71 per protocol, including the collection of at least 45 anogenital swabs during Days 43 to 71.
2. Enrolled into this trial within 56 days of completing Day 71 of GEN-003-002.
3. Willing and able to provide written informed consent.
4. Willing to perform and comply with all study procedures including attending clinic visits as scheduled.
5. Men and women of childbearing potential, must be willing to practice a highly effective method of contraception that may include, but is not limited to, abstinence, monogamous relationship with vasectomized partner, vasectomy, licensed hormonal methods, intrauterine device (IUD), or barrier method (e.g., condom, diaphragm) for 28 days before and 90 days after receiving Study Drug.

Exclusion Criteria:

1. On suppressive antiviral medication within 7 days prior to the first dose of Study Drug.
2. Collection of less than 45 anogenital swabs during Days 43 to 71 of the GEN-003-002 study.
3. History of any form of ocular Herpes Simplex Virus (HSV) infection, HSV-related erythema multiforme, or herpes meningitis or encephalitis.
4. Immunocompromised individuals, including those receiving immunosuppressive doses of corticosteroids (more than 20 mg of prednisone given daily or on alternative days for 2 weeks or more within 6 months prior to the first dose of Study Drug, any dose of corticosteroids within 30 days of the first dose of Study Drug, or high dose inhaled corticosteroids [> 960 μg/day of beclomethasone dipropionate or equivalent]) or other immunosuppressive agents.
5. Presence or history of autoimmune disease, regardless of current treatment.
6. Positive serologic test for Human Immunodeficiency Virus (HIV-1) or hepatitis C infection (in the absence of a negative PCR result); positive hepatitis B surface antigen (HBsAg) within 6 months prior to the first dose of Study Drug.
7. Clinically significant laboratory abnormality or a value ≥ Grade 2 within 56 days prior to the first dose of Study Drug.
8. Receipt of blood products within 90 days prior to the first dose of Study Drug.
9. Receipt of a live vaccine within 28 days prior to or a subunit vaccine within 14 days prior to the first dose of Study Drug or planned vaccination within 30 days following the last dose of Study Drug.
10. Pregnant or nursing women.
11. History of drug or alcohol abuse that, in the opinion of the Investigator, would interfere with the patient's ability to comply with the requirements of the study.
12. Other active, uncontrolled co-morbidities that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with the study requirements.

NOTE: Subjects who are taking a medication to control an underlying co-morbidity may be enrolled if there have been no changes to their medication within 60 days prior to the first dose of Study Drug.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Factorial Assignment
• Masking: Quadruple

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: GEN-003 Vaccine 30μg / Matrix-M 25μg; GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (25 μg), administered as a 0.5 mL intramuscular (IM) injection.	Biological: GEN-003 Vaccine (30μg of each antigen); HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D; Other Names: HSV Vaccine; Biological: Matrix-M2 Adjuvant (25μg); Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.; Other Names: Adjuvant; MM2
Experimental: GEN-003 Vaccine 30μg / Matrix-M2 50μg; GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (50 μg), administered as a 0.5 mL intramuscular (IM) injection.	Biological: GEN-003 Vaccine (30μg of each antigen); HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D; Other Names: HSV Vaccine; Biological: Matrix-M2 Adjuvant (50μg); Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.; Other Names: Adjuvant; MM2
Experimental: GEN-003 Vaccine 30μg / Matrix-M2 75μg; GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (75 μg), administered as a 0.5 mL intramuscular (IM) injection.	Biological: GEN-003 Vaccine (30μg of each antigen); HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D; Other Names: HSV Vaccine; Biological: Matrix-M2 Adjuvant (75μg); Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.; Other Names: Adjuvant; MM2
Experimental: GEN-003 Vaccine 60μg / Matrix-M2 25μg; GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (25 μg), administered as a 0.5 mL intramuscular (IM) injection.	Biological: Matrix-M2 Adjuvant (25μg); Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.; Other Names: Adjuvant; MM2; Biological: GEN-003 Vaccine (60μg of each antigen); HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D; Other Names: HSV Vaccine
Experimental: GEN-003 Vaccine 60μg / Matrix-M2 50μg; GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (50 μg), administered as a 0.5 mL intramuscular (IM) injection.	Biological: Matrix-M2 Adjuvant (50μg); Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.; Other Names: Adjuvant; MM2; Biological: GEN-003 Vaccine (60μg of each antigen); HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D; Other Names: HSV Vaccine
Experimental: GEN-003 Vaccine 60μg / Matrix-M2 75μg; GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (75 μg), administered as a 0.5 mL intramuscular (IM) injection.	Biological: Matrix-M2 Adjuvant (75μg); Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.; Other Names: Adjuvant; MM2; Biological: GEN-003 Vaccine (60μg of each antigen); HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D; Other Names: HSV Vaccine

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Impact on clinical HSV-2 disease based on time to recurrence and lesion rate	53 weeks

Secondary Outcome Measures

Outcome Measure	Time Frame
Number of patients with adverse events as a measure of safety and tolerability	57 weeks

Collaborators and Investigators

• Sponsor: Genocea Biosciences, Inc.

Study record dates

Study Major Dates

• Study Start: January 1, 2015
• Primary Completion (Actual): June 1, 2016
• Study Completion (Actual): June 1, 2016

Study Registration Dates

• First Submitted: November 20, 2014
• First Submitted That Met QC Criteria: November 20, 2014
• First Posted (Estimate): November 24, 2014

Study Record Updates

• Last Update Posted (Actual): October 16, 2017
• Last Update Submitted That Met QC Criteria: October 6, 2017
• Last Verified: October 1, 2017

More Information

Terms related to this study

• Keywords: vaccine; HSV; Herpes; genital infection
• Additional Relevant MeSH Terms: Skin Diseases; Virus Diseases; Infections; Communicable Diseases; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; DNA Virus Infections; Skin Diseases, Infectious; Skin Diseases, Viral; Herpesviridae Infections; Herpes Simplex; Herpes Genitalis; Physiological Effects of Drugs; Immunologic Factors; Vaccines
• Other Study ID Numbers: GEN-003-002a